Andrea Pilotto, MD, University of Brescia, Brescia, Italy explains the significance of synaptic markers neurogranin, SNAP25, and the newly defined CAP2 in Alzheimer’s disease (AD). Accumulating evidence shows that these markers are present at high levels in the early stages of AD. Furthermore, both neurogranin and SNAP25 are found at higher levels in AD compared to other neurodegenerative disorders. This may be due to the regions damaged in AD being richer in both biomarkers, particularly SNAP25. These properties implicate SNAP25 as a potential diagnostic marker. CAP2, known to play a role in synaptic plasticity, is a newly validated synaptic marker that also shows increased presence in the CSF in the early stages of AD compared to later stages, which could suggest its involvement in a compensation mechanism. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
